SCHEMBL2644769

SCHEMBL2644769

CC1(C)Cc2c(Oc3ccc(C(=O)NC4CCC4)c(F)c3)cc(C(=O)O)cc2O1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.56
EZH2 Q15910 2/20 0.45
HRH3 Q9Y5N1 3/20 0.40
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PKM P14618 1/20 0.36
LPAR1 Q92633 2/20 0.35
LPAR5 Q9H1C0 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CRBN Q96SW2 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
AURKA O14965 1/20 0.35
LCK P06239 1/20 0.35
MET P08581 1/20 0.35
KDR P35968 1/20 0.35
TEK Q02763 1/20 0.35
CYSLTR2 Q9NS75 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
PTGES O14684 1/20 0.34
GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2644938 0.97 GCK (0.55) GCKEZH2HRH3RAB9AL3MBTL1
SCHEMBL2643938 0.88 GCK (0.59) GCKEZH2LPAR1LPAR5ALDH1A1
SCHEMBL2645431 0.88 GCK (0.58) GCKEZH2LPAR1LPAR5ALDH1A1
SCHEMBL2643748 0.86 GCK (0.54) GCKEZH2LPAR1LPAR5ALDH1A1
SCHEMBL2643773 0.86 GCK (0.54) GCKEZH2LPAR1LPAR5ALDH1A1
SCHEMBL644210 0.85 GCK (0.78) GCKEZH2HRH3
SCHEMBL2644107 0.85 GCK (0.56) GCKEZH2LPAR1LPAR5ALDH1A1
SCHEMBL2644110 0.85 GCK (0.54) GCKEZH2RAB9APKMLPAR1
SCHEMBL2644082 0.83 GCK (0.53) GCKEZH2LPAR1LPAR5ALDH1A1
SCHEMBL2645491 0.83 GCK (0.56) GCKEZH2LPAR1LPAR5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 GCK 1/4885EZH2 3015/4885HRH3 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.